EGFR and rectal cancer: MUTKRAS is a negative predictor of benefit to anti-EGFR antibodies in colo-rectal cancer, while it seems to be a negative predictor of response to EGFR-TKIs in EGFR wild type (WTEGFR) NSCLC patients [15].